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On the 1st of April 1999, the National Institute of Clinical Excel-
lence (NICE) was established to evaluate the clinical and cost
effectiveness of various different medical technologies including
pharmaceuticals. Initially, a technology is assessed, after which
provisional and then ﬁnal advisory documents (PAD and FAD)
are produced prior to the publication of clinical guidance with
particular attention being paid to high quality adequately powered
Randomised Controlled Trials (RCT’s). Interested parties can
submit evidence at the start of the process and can then respond
to the provisional guidance released as part of the PAD. They
can also appeal after the ﬁnal guidance is produced, but if this
appeal is unsuccessful, the process stops and the ‘Technology
Appraisal Guidance (TAG)’ is published on the NICE web site
and as a booklet.
The guidance on the use of irinotecan, oxaliplatin and ralti-
trexed for the treatment of advanced colorectal cancer (CRC)
was published in March 2002 (NICE, 2002). The process began
in August 2000 and reports from the pharmaceutical industry,
UKCCCR, CancerBACUP and Macmillan Cancer relief were
submitted by December of that year. Advice was also sought from
the MRC trials unit, Royal College of General Practitioners and
the appraisal committee had a single external expert (was this
enough?) and patient advocate (NICE, 2002). The published
guidance advocates the use of 5-ﬂuorouracil and folinic acid
(5FU/FA) initially, reserving single-agent irinotecan for when this
treatment fails. Oxaliplatin was recommended for use in the very
few cases where inoperable liver metastases can potentially be
made operable with chemotherapy. The use of raltitrexed was
not recommended at all.
We are therefore left with the unpalatable situation of following
guidance that limits us to using a 40-year-old drug as ﬁrst-line
treatment in the majority of patients with advanced CRC. This
guidance is at odds with the Oncologic Drugs Advisory Committee
of the US Food and Drug Administration (FDA), which approved
the ﬁrst-line use of combined irinotecan and 5FU/FA (Ir.5FU/FA)
in March 2000. It is also at odds with much of Europe, where
either oxaliplatin or irinotecan are regularly used in combination
with 5FU/FA in this group of patients. In addition, during the peri-
od of consultation prior to the ﬁnal Guidance, many purchasers
withheld funding for these drugs and therefore patients in NHS
Trusts were potentially denied a clinically effective treatment for
approximately 18 months.
The evidence for the use of Ir.5FU/FA in the ﬁrst-line treat-
ment of patients with advanced CRC is very compelling. Two
large randomised trials have been published (Douillard et al,
2000; Saltz et al, 2000) that show a signiﬁcant survival beneﬁt
when patients receive an Ir.5FU/FA combination compared to
5FU/FA alone. More than 1000 patients were entered into these
studies and, amongst patients randomised to receive ‘standard’
5FU/FA, there was signiﬁcant ‘cross-over’ to irinotecan-based
therapy upon disease progression (31% and 56% in the two
studies, respectively). None-the-less there was still a 3-month
survival beneﬁt in the group of patients that initially received
Ir.5FU/FA. This, along with historical 5FU data, suggests that
the survival beneﬁt would probably be even greater than 3
months if ‘cross-over’ were not allowed. It also suggests that
giving irinotecan ‘up-front’ is advantageous, given that patients
in this arm fared better even though a considerable number of
patients in the control arms also crossed-over to receive irinote-
can after failing 5FU/FA. NICE also evaluated other studies that
had been published as abstracts including the FOLFOX/FOLFIRI
data (Tournigand et al, 2001). This study randomised patients to
receive either oxaliplatin and 5FU/FA (Ox.5FU/FA) or Ir.5FU/FA
initially, crossing over to receive the other arm when the disease
progressed. The response rate to both arms was approximately
57% and the median survival exceeds that seen in any previous
advanced CRC studies (approx. 21 months in both treatment
arms – data presented later at the American Society of Clinical
Oncology (ASCO), San Francisco, 2001). Publication of this
important paper is expected imminently. To summarise, the
evidence for using irinotecan ‘up-front’ in patients with
advanced CRC is very strong and importantly, all the available
data points in the same direction: increased survival. We feel
therefore, that it is perverse that NICE have come to this
conclusion given the weight of the data supporting the use of
irinotecan in this situation.
Combinations of Irinotecan with 5FU/FA are well tolerated and
a patient’s quality of life (QoL) is no worse than with 5FU/FA (de
Gramont regimen) alone (Douillard et al, 2000). However, single
agent irinotecan, as recommended by NICE, is given at approxi-
mately twice the dose and the prevalence of alopecia, and grade
III/IV nausea (15% vs 2.1%), diarrhoea (22% vs 13.1%) and vomit-
ing (14% vs 2.8%) is increased compared to the 2-weekly
irinotecan/de Gramont schedule commonly used in the UK
(Cunningham et al, 1998; Douillard et al, 2000). Received 18 April 2002; accepted 23 April 2002
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advanced CRC as recommended by the FDA, they would receive a
single period of ‘active treatment’ until disease progression. Upon
disease progression, they may then have the opportunity to enter
appropriate clinical trials or receive best supportive care (BSC).
If we follow the NICE guidance, patients would receive 5FU/FA
until disease progression followed by single agent irinotecan if they
are still ﬁt enough. This would lead to two periods of ‘active’ treat-
ment no doubt amounting to 6 to 12 months of chemotherapy,
when patients would receive more intensive follow-up than if they
received BSC. This is expensive in terms of staff time and more
importantly patient time as well as expensive in monetary terms.
More out-patient visits will be required, more demand on phar-
macy services will be generated, out-patient congestion will be
increased for longer periods, more CT scans, ultra-sounds and
chest X-rays will be required and there will be an increased burden
on the hospital pathology departments. In this issue, Cunningham
et al support this view and state that their data for cost effective-
ness and clinical evidence ‘strongly support the use of irinotecan
and 5FU/FA in the setting of ﬁrst line therapy of metastatic
CRC’ (Cunningham et al, 2002). They have shown a cost-effective-
ness ratio per life year gained (LYG) of £14 794, which compared
favourably to a range surmised from a recent Department of
Health review. The cost-effectiveness of different 5FU regimens is
also discussed in this issue (see Hale et al, 2002).
The oxaliplatin studies (de Gramont et al, 2000; Giacchetti et al,
2000) also suffered from the crossover effect from the control arms
to the oxaliplatin-based therapy on disease progression. In particu-
lar, the randomised study by de Gramont et al (2000) showed a
much higher than expected median overall survival in the control
5FU/FA arm because of the crossover of these patients to the oxali-
platin-containing arm or because they also received irinotecan at
some point. If crossover was not allowed, a signiﬁcant survival
beneﬁt may well have been achieved. What is now becoming
evident is that the use of all three drugs (Ir, Ox, 5FU) in different
combinations and sequencing leads to improved patient survival
(Tournigand et al, 2001). If we follow the NICE guidelines, then
the survival of patients with advanced CRC in England and Wales
will no-doubt be reduced compared to the rest of Europe and USA,
since our freedom to prescribe these newer agents will be restricted.
Very few patients have inoperable liver metastases at presenta-
tion, that can be down-staged enough with chemotherapy to
make them operable. Therefore the recommendation by NICE that
Ox.5FU/FA combination chemotherapy should be used in this
scenario will only beneﬁt a very small number of patients. The
guidance is only based on retrospective data from two small studies
(Adam et al, 2001; Bismuth et al, 1996; Giacchetti et al, 2000). This
recommendation is therefore surprising given that they were unable
to recommend ﬁrst-line Ir.5FU/FA combinations with evidence
based on two large prospective RCT’s. NICE have also failed to
adequately deﬁne the type of patients for which this treatment
would be appropriate. The characteristics of such patients will need
to be clearly deﬁned at a multidisciplinary level, particularly in
conjunction with hepatobiliary surgeons. None-the-less this unex-
pected recommendation is welcomed, and will allow us to use
oxaliplatin in this setting.
The use of raltitrexed in patients with advanced CRC was also
not recommended by NICE. We feel that this decision is again
wrong given that patients with signiﬁcant heart disease will be
denied an effective treatment. 5-Fluorouracil should be used with
caution or should even be contraindicated in patients with trouble-
some arrhythmias and ischaemic heart disease. At present the only
effective alternative is raltitrexed and we feel that this drug should
be made available and used with caution in this particular situa-
tion. NICE may maintain that they only produce ‘guidance’,
however, their documents are often taken literally by funding
bodies and so money for raltitrexed, for example, is unlikely to
be made available despite clinical need.
We therefore need to ask, ‘Why hasn’t NICE followed North
America and Europe’s lead and recommended more widespread
use of these drugs in England and Wales?’ We believe that cost
was the main issue. They have essentially restricted the use of irino-
tecan by accepting that only 75% of patients (possibly an
overestimate) will still be ﬁt enough to receive this drug after
ﬁrst-line 5FU/FA (NICE, 2002). Therefore, 25% of patients who
were initially deemed ﬁt enough to receive a ﬁrst-line combination
of Ir.5FU/FA will in fact be denied this therapy because their
disease has progressed and ﬁtness has deteriorated. Rationing
patient’s treatment in this manner is not the way to save money.
Additionally, the use of two active periods of treatment as outlined
above is likely to prove this strategy a ‘false economy’.
One of the government aims is to remove ‘post-code prescrib-
ing’. NICE have gone some way to achieving this by allowing us
to prescribe irinotecan for patients who fail ﬁrst-line 5FU/FA. This
is certainly a welcome improvement for hospitals not previously
able to prescribe this drug at all. However, NICE would have done
even better if they had allowed us more freedom to prescribe these
newer agents appropriately, in the same manner as in North Amer-
ica and much of Europe. We would then get closer to achieving the
aims of the National Cancer Plan. For now, NHS patients in
England and Wales will have to accept inferior treatment and a
reduced life expectancy.
A House of Commons Science and Technology Committee
Special Report on cancer research was published on the 20th of
March 2002. The report claims that there is insufﬁcient funding
from the Department of Health for cancer research. This may
not surprise many of us since it has long been felt that we rely
too much on the various charities and the pharmaceutical industry.
To continue with internationally accepted research, we need to
have a control arm that is acceptable to the rest of the world. If
North America are using irinotecan regularly and Europe are using
either this or oxaliplatin, do we continue to simply use 5FU/FA?
Research using just a 5FU/FA-control arm will no longer be
considered relevant by others outside the UK. Gaining funding will
no doubt be harder, considering that these bodies, quite rightly,
want to fund research that is up-to-date and internationally
accepted.
We have yet to mention the patient’s perspective. Given that
informed consent and patient choice are becoming increasingly
paramount, it would be interesting to hear their view if all of
the facts were presented to them. Would they prefer the NICE
strategy or the treatment approved by the FDA? – One can only
speculate, but we think the answer would be obvious.
NICE is due to review this guidance in 2005 when data from the
MRC CRO8 (FOCUS) study becomes available. Given that the
results from this study are unlikely to dramatically alter the balance
of information presently available, this seems tardy. By that time,
the use of these newer agents in North America and Europe will
have become established and we will trail even further behind in
the treatment of advanced CRC. Results will also become available
from a number of adjuvant colon cancer studies that have recently
closed (X-ACT, MOSAIC, PETTAC3). If the outcomes are favour-
able, then it is possible that these trials may prove that these newer
agents are beneﬁcial in this situation, even though we are unable to
prescribe them for patients with advanced CRC.
The 5-year survival ﬁgures for the UK are already extremely
poor compared to Europe and North America (41, 47 and 63%
respectively) (National Statistics (2000); Ofﬁce for National Statis-
tics, 2000). In a typically political statement, one of the aims of the
National Cancer Plan is to ‘never fall behind again’. However, in
the case of CRC, it is perhaps difﬁcult to fall behind when we
haven’t even reached the baseline from which to fall behind from!!
Hopefully some of the money announced in the recent budget can
be used to provide modern, effective, chemotherapy for patients
with this awful disease. Then perhaps we can at last compete with
the rest of the world.
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